Characteristics of adverse events of inactivated quadrivalent influenza vaccine in healthy populations: a meta-analysis based on randomized controlled trials
In brief
Quadrivalent flu vaccine studies found adverse events in 43% of recipients
Across 29 randomized trials involving 28,410 healthy participants, 43% had a reported adverse event after quadrivalent flu vaccination; serious adverse events occurred in under 1%. Compared with trivalent vaccine, quadrivalent vaccine was linked to more overall and local events, but not more systemic or serious events. Differences in study methods and settings may affect these estimates.
- Journal
- Frontiers in public health (Q1)
- Published
- 3 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Liuyang Kang, Jing Yang, Jingru Cheng, Shaowen Tang, Youcai An, Hang Tao, et al.
- PMID
- 43047547
- DOI
- 10.3389/fpubh.2026.1954409
Why clinicians should know about it
- Picked for Public Health, Environmental and Occupational Health (top studies of the week, 22 November 2026): Influenza-vaccine safety evidence relevant to vaccination programmes
Abstract
BACKGROUND: Influenza constitutes a critical global public health issue, and quadrivalent inactivated influenza vaccine (QIV) is widely used, yet systematic analyses of its adverse events (AEs) remain lacking. This meta-analysis aimed to characterize AEs following QIV vaccination in healthy populations. METHODS: We searched for randomized controlled trials (RCTs) of QIV vaccination in healthy populations, extracted AE data from QIV groups, pooled incidence rates, and compared the risks of AEs between QIV and trivalent influenza vaccine (TIV) using a random-effects model. Subgroup analyses, meta-regression, and sensitivity analyses were applied to explore heterogeneity and result robustness. Publication bias was evaluated utilizing Begg's and Egger's tests. RESULTS: A total of 29 studies published from 2008 to 2025 were included, involving 28,410 participants with 8,197 reported AEs in total. The overall incidence of AEs after QIV vaccination in healthy populations was 43% (95% CI: 31%-54%), with an incidence of 27% (95% CI: 18%-37%) for local AEs and 20% (95% CI: 14%-26%) for systemic AEs. The incidence of SAEs was 0.96%. The QIV group showed significantly elevated risks of overall and local AEs relative to TIV (P < 0.05), while no significant differences were detected in systemic AEs and SAEs between the two groups (P > 0.05). Heterogeneity was associated with study period, study region, AE collection duration, and vaccine origin. Sensitivity analyses and publication bias analyses confirmed result stability. CONCLUSION: This study summarizes AE incidence and features after QIV in healthy populations, supporting clinical vaccination and post-vaccination safety surveillance with exploratory data. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233388, identifier CRD420251233388.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.